Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 03, 2025 16:05 ET | Source: Myriad Genetics, Inc.

Myriad Genetics Reports Third Quarter 2025 Financial Results; Reiterates 2025 Financial Guidance Following Continued Solid Execution

Myriad Genetics today announced financial results for its third quarter ended September 30, 2025.
October 31, 2025 09:05 ET | Source: Myriad Genetics, Inc.

New Post-Hoc Analysis Shows Patients Whose Clinicians Had Access to GeneSight Results for Depression Treatment Are More Likely to Feel Better Sooner

SALT LAKE CITY, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced a post-hoc analysis of the...
October 27, 2025 16:15 ET | Source: Myriad Genetics, Inc.

Myriad Genetics to Release Third Quarter 2025 Financial Results on November 3, 2025

Myriad Genetics will hold its third quarter 2025 earnings conference call at 4:30 pm ET on Monday, Nov. 3, 2025
October 14, 2025 08:00 ET | Source: Myriad Genetics, Inc.

Myriad Genetics Adds F8, FXN Genes to Foresight Universal Plus Panel

SALT LAKE CITY, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced it has added two genes, F8...
September 23, 2025 08:00 ET | Source: Myriad Genetics, Inc.

Myriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid Biopsy

SALT LAKE CITY and BOSTON, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics (Nasdaq: MYGN), a leader in molecular diagnostic testing and precision medicine, and SOPHiA GENETICS (Nasdaq: SOPH), an...
September 04, 2025 19:00 ET | Source: Myriad Genetics, Inc.

Myriad Genetics Announces Precise MRD Clinical Data Published in The Lancet Oncology

SALT LAKE CITY, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced The Lancet Oncology...
September 03, 2025 16:30 ET | Source: Myriad Genetics, Inc.

New Meta-Analysis Demonstrates that Access to the GeneSight Test Can Significantly Improve Response and Remission Rates for Patients with Depression

SALT LAKE CITY, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced the publication of a new...
August 27, 2025 16:05 ET | Source: Myriad Genetics, Inc.

Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences

SALT LAKE CITY, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced Myriad management will...
August 18, 2025 08:30 ET | Source: Myriad Genetics, Inc.

Myriad Genetics Appoints Ben Wheeler Chief Financial Officer

SALT LAKE CITY, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Ben Wheeler has been...
August 13, 2025 08:00 ET | Source: Myriad Genetics, Inc.

New Myriad Genetics Survey Uncovers Women Fear Screenings—But Feel Reassured by the Results

SALT LAKE CITY, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today released findings from its latest...